Shares of PEGBIO CO-B (02565) experienced a significant intraday surge, climbing more than 13% at one point during the morning session.

At the time of writing, the stock was up 4.27%, trading at HK$8.30 with a turnover of HK$175 million.

The company announced that research findings for its self-developed circular RNA-encoded GLP-1 analog, CR059, have been accepted for presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes in 2026.

The research has also been selected for the oral discussion session.

This acceptance follows the prior selection of CR059-related research for a Late-Breaking Abstract at the American Diabetes Association Scientific Sessions.

The consecutive recognition by these two premier international academic conferences in the fields of diabetes and metabolic diseases signifies high-level attention and validation for CR059 and the company's circular RNA technology platform.

The company believes the core innovative value of CR059 lies in its potential to move beyond the current weekly dosing regimen predominant for existing GLP-1 drugs.

It aims to extend towards ultra-long-acting treatment with dosing intervals of a month or longer, potentially even quarterly.

Should this technological pathway succeed in subsequent clinical translation, it could significantly reduce the long-term dosing burden for patients with chronic metabolic diseases.

This advancement would improve treatment adherence and long-term management efficiency, offering a new generation of solutions for obesity, type 2 diabetes, and related metabolic disorders distinct from existing peptide-based drugs.